Annalee Armstrong

Biotech industry analyst Annalee Armstrong and expert Max Bayer dive into the top money raisers in biotech for 2023. They discuss funding trends, the biotech financing landscape, and the stories behind the numbers. From the rise of dual-track processes to strategic partnerships and upcoming biotech IPOs, this episode is a must-listen for industry enthusiasts.

Annalee Armstrong, a key figure in Fierce Biotech's annual reports, and Gabrielle Masson, a presenter for the Fierce 15 at NYSE, delve into the fascinating selection process for this year's Fierce 15. They reveal the unique qualities that set these innovative biotech companies apart, from groundbreaking RNA therapies inspired by nature to the rise of women-led firms. The duo also shares insights into collaborations tackling obesity and mental health, showcasing the vibrant landscape of biotech's future.

Fierce Biotech's Annalee Armstrong and Fierce Pharma's Ben Adams discuss the Best Biotech Name and Drug Names tournaments. They explore what makes a company or drug name impactful, the tournament results, and the winning names like Wainua, Werewolf, and Obsidian. The conversation touches on the importance of memorable, pronounceable, and distinct names in the biotech and drug industry.

Fierce Biotech members Annalee Armstrong and Gabrielle Masson discuss the challenges and advancements in cell therapy, including a notable shift towards autoimmune treatments, manufacturing constraints, and the potential impact of CAR-T therapy in various medical fields.

This podcast looks back at the year in biotech, focusing on massive industry layoffs and favorite stories, including a Taylor Swift appearance. Topics also include IPO trends, Alzheimer's meds, and the impact on the Down syndrome community.